The Dr. David M. Kovitz Visiting Professorship was established to stimulate interest and development in education, training and research in the area of cancer and diabetes. The fund supports a lectureship which provided the opportunity for distinguished scholars from around the world to interact with faculty, students and members of the Calgary community while visiting our University.

Dr. David M. Kovitz, a well-respected dentist and businessman in Calgary, originally established the endowment in 1988. The fund was matched by the Government of Alberta and received further support by his family and friends. In 1992, Dr. Kovitz passed away but through his gift to the University of Calgary, the Visiting Professorship is a lasting tribute to his commitment to excellence and the advancement of medical research and education.

Past Dr. David M. Kovitz Lecturers:

1992 Dr. Paul Talalay
1993 Dr. Edmond Fischer
1994 Dr. Meng H. Tan
1995 Dr. Frank Rauscher III
1996 Dr. Joseph Bertino
1997 Dr. Ronald Klein
1998 Dr. Trevor Powles
1999 Dr. Robert Weinberg
2000 Dr. Barry I. Posner
2001 Dr. Morris J. Birnbaum
2002 Dr. C. Ronald Kahn
2003 Dr. Nader Abraham
2004 Dr. Frances M. Ashcroft
2005 Dr. Jeannette Ward
2006 Dr. Edward H. Leiter
2007 Dr. Leonard C. Harrison
2008 Dr. Daniel Von Hoff
2009 Dr. Camillo Ricordi
2010 Dr. Paul Nurse
2011 Dr. Linda Wicker
2012 Dr. Joan S. Brugge
2013 Dr. Philippe Froguel
2014 Dr. Morag Park
2015 Dr. Emil Unanue
2016 Dr. Nada Jabado
2017 Dr. David Sutherland

“The Development of Safe and Effective Engineered T Cell Therapies for Hematologic Malignancies”

Tuesday, September 18, 2018
1:00-2:00pm
Theatre 4, HSC
Reception: 2:00-3:00pm
HRIC Atrium

Dr. Stanley Riddell
Professor, Department of Medicine, University of Washington
Dr. Stanley Riddell, is a full member of the Program in Immunology of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, and a professor in the Department of Medicine at the University of Washington. Dr. Riddell has been elected to the Association of American Physicians, and his current work builds on his previous accomplishments and seeks to identify further ways to improve the effectiveness of T cell immunotherapies.

Dr. Riddell is an expert in cell transplantations and T cell-based immunotherapies, and has used them to treat many patients with lymphoma and leukemia. He’s contributed many advances that are widely used in cell-based immunotherapy approaches, including CAR T cells, and also led the first clinical trial that utilized adoptively transferred T cells.

Dr. Riddell’s lab has developed critical techniques for isolation, expansion, genetic modification and reinfusion of therapeutic T cells, and for monitoring patient safety, T cell persistence, migration and function post-infusion. These include state-of-the-art ways to identify the tumor cell “antigens” recognized by T cells. Many are now broadly employed in adoptive immunotherapies for cancer that use natural targeting molecules called T cell receptors (TCRs) or use synthetic TCR- and antibody-related molecules known as chimeric antigen receptors (CARs).

Program

Welcoming Remarks
Dr. Greg Cairncross
Director, Charbonneau Cancer Institute

Introduction of Dr. Stanley Riddell
Dr. Doug Mahoney
Assistant Professor, University of Calgary

The 2018 Dr. David M. Kovitz Lecture
“The Development of Safe and Effective Engineered T Cell Therapies for Hematologic Malignancies”

Closing Remarks
Dr. Jennifer Chan
Deputy Director, Charbonneau Cancer Institute

Please join us for a reception in the HRIC Atrium